MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation

Biomedicine and Pharmacotherapy

Volumn 68, Issue 1, 2014, Pages 7-12

  Li, Peipei ^a,b   Ma, Lijie ^a   Zhang, Yongjuan ^c   Ji, Fuyun ^d   Jin, Faguang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b HARRISON INTERNATIONAL PEACE HOSPITAL   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

KIT; MDR; MiR 137; SCLC

Indexed keywords

KIT; MDR; MIR-137; SCLC;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-KIT; SMALL CELL LUNG CARCINOMA; TRANSFECTION;

EID: 84895070082     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.12.002     Document Type: Article

References (30)

1. Lee H., Jin G.Y., Han Y.M., Chung G.H., Lee Y.C., Kwon K.S., et al. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol 2012, 35:343-350.
2. Zhu G.Y. [To improve the survival rate of patients suffering from locally advanced non-small cell lung cancer with combination of radiotherapy and chemotherapy]. Zhonghua Jie He He Hu Xi Za Zhi 2007, 30:88-90.
3. Sharom F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9:105-127.
4. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Blower P.E., Chung J.H., Verducci J.S., Lin S., Park J.K., Dai Z., et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008, 7:1-9.
6. Nasser M.W., Datta J., Nuovo G., Kutay H., Motiwala T., Majumder S., et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008, 283:33394-33405.
7. Eitan R., Kushnir M., Lithwick-Yanai G., David M.B., Hoshen M., Glezerman M., et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009, 114:253-259.
8. Deng Y., Deng H., Bi F., Liu J., Bemis L.T., Norris D., et al. MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma cell lines. Int J Biol Sci 2011, 7:133-137.
9. Zhu X., Li Y., Shen H., Li H., Long L., Hui L., et al. miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai) 2013, 45:80-86.
10. Zhu X., Li Y., Shen H., Li H., Long L., Hui L., et al. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett 2013, 587:73-81.
11. Ali S., Ali S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 2007, 401:38-45.
12. Montero J.C., Lopez-Perez R., Miguel J.F.S, Pandiella A. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica 2008, 93:851-859.
13. Yoshida C., Tsuji A.B., Sudo H., Sugyo A., Kikuchi T., Koizumi M., et al. Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer. PLoS One 2013, 8:e59248.
14. Edris B., Willingham S., Weiskopf K., Volkmer A.K., Volkmer J.P., Muhlenberg T., et al. Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Oncoimmunology 2013, 2:e24452.
15. Lv A., Li Z., Tian X., Guan X., Zhao M., Dong B., et al. SKP2 high expression, KIT exon 11 deletions, and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors. PLoS One 2013, 8:e62951.
16. Felli N., Fontana L., Pelosi E., Botta R., Bonci D., Facchiano F., et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005, 102:18081-18086.
17. Kim W.K., Park M., Kim Y.K., Tae Y.K., Yang H.K., Lee J.M., et al. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res 2011, 17:7584-7594.
18. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 123:372-379.
19. Di Leva G., Croce C.M. The role of microRNAs in the tumorigenesis of ovarian cancer. Front Oncol 2013, 3:153.
20. Shang Y., Zhang Z., Liu Z., Feng B., Ren G., Li K., et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2013.
21. Yang T., Zheng Z.M., Li X.N., Li Z.F., Wang Y., Geng Y.F., et al. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood) 2013.
22. Yin W., Wang P., Wang X., Song W., Cui X., Yu H., et al. Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells. Braz J Med Biol Res 2013, 46:546-554.
23. Chen D.L., Wang D.S., Wu W.J., Zeng Z.L., Luo H.Y., Qiu M.Z., et al. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis 2013, 34:803-811.
24. Chen Q., Chen X., Zhang M., Fan Q., Luo S., Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 2011, 56:2009-2016.
25. Wiklund E.D., Gao S., Hulf T., Sibbritt T., Nair S., Costea D.E., et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One 2011, 6:e27840.
26. Zhao Y., Li Y., Lou G., Zhao L., Xu Z., Zhang Y., et al. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One 2012, 7:e39102.
27. Luo C., Tetteh P.W., Merz P.R., Dickes E., Abukiwan A., Hotz-Wagenblatt A., et al. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 2013, 133:768-775.
28. Balaguer F., Link A., Lozano J.J., Cuatrecasas M., Nagasaka T., Boland C.R., et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010, 70:6609-6618.
29. Kikuchi H., Yamamoto M., Hiramatsu Y., Baba M., Ohta M., Kamiya K., et al. Effect of loss of heterozygosity of the c-kit gene on prognosis after hepatectomy for metastatic liver gastrointestinal stromal tumors. Cancer Sci 2007, 98:1734-1739.
30. Kikuchi H., Miyazaki S., Setoguchi T., Hiramatsu Y., Ohta M., Kamiya K., et al. Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene. Anticancer Res 2012, 32:4105-4109.